Ocugen (OCGN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was called to order and held virtually to maximize accessibility and participation.
Directors, management, and the independent accounting firm were introduced.
The agenda and rules of conduct were outlined, with instructions for stockholder participation and voting.
Board and executive committee updates
Board nominees Kirsten Castillo and Satish Chandran were presented for election as Class III directors for a three-year term.
Committee chairs for Science and Technology, Nominating and Corporate Governance, Audit, and Compensation were introduced.
Shareholder proposals
Four items were presented: election of directors, ratification of the accounting firm, advisory approval of executive compensation, and advisory vote on the frequency of future compensation votes.
Latest events from Ocugen
- Vote sought to increase authorized shares by 250 million to support growth and financing flexibility.OCGN
Proxy filing20 Jul 2026 - Late-stage gene therapies for major retinal diseases advance toward global approvals by 2028.OCGN
Piper Sandler Virtual Ophthalmology Day14 Jul 2026 - Gene therapy trials advanced, net loss narrowed, and $32.6M raised to extend cash runway.OCGN
Q2 20249 Jul 2026 - Gene therapy pipeline advances and $65M financing extend cash runway into Q1 2026, but funding risks persist.OCGN
Q3 20248 Jul 2026 - Gene-agnostic therapies show strong safety, efficacy, and major market potential in retinal diseases.OCGN
Status Update8 Jul 2026 - OCU410 reduced GA lesion growth by 31% at 12 months with strong safety and one-time dosing.OCGN
Study update8 Jul 2026 - Three gene therapies for retinal diseases advance toward global approval, targeting broad patient needs.OCGN
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference4 Jun 2026 - Advancing gene therapies for major retinal diseases, aiming for three BLAs by 2028.OCGN
Stifel 2026 Virtual Ophthalmology Forum26 May 2026 - Advanced gene therapy pipeline, secured funding, and extended cash runway into late 2026.OCGN
Q4 202514 May 2026